Medipal Holdings (7459) AI Stock Analysis

• Market Cap: ¥463.51B
• Dividend Yield: 2.55%
• Average Volume (3M): 381.10K
• Price to Earnings (P/E): 12.8
• Beta (1Y): 0.47
• Revenue Growth: 3.51%
• EPS Growth: 5.22%
• Country: JP
• Employees: 13,075
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): 46.17
• Shares Outstanding: 219,226,040
• 10 Day Avg. Volume: 370,130
• 30 Day Avg. Volume: 381,100
• PEG Ratio: -8.97
• Price to Book (P/B): 0.79
• Price to Sales (P/S): 0.13
• P/FCF Ratio: 9.42
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥2,739.45
• Price Target Upside: 6.68% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 68 Neutral
• Price Target: ¥2,720.00 ▲(5.92% Upside)

Medipal Holdings' overall stock score is driven by its solid financial performance and reasonable valuation. The technical analysis indicates a bearish trend, which slightly offsets the positive financial outlook. The lack of earnings call data and corporate events does not impact the score.

Medipal Holdings Business Overview & Revenue Model

Company Description

Medipal Holdings (7459) is a leading Japanese company operating in the healthcare and medical supplies sector. The company primarily focuses on the manufacture and distribution of medical products, including pharmaceuticals, medical devices, and healthcare-related services. Medipal Holdings serves a diverse range of customers, including hospitals, clinics, and pharmacies, and is committed to improving healthcare outcomes through innovative solutions and high-quality products.

How the Company Makes Money

Medipal Holdings generates revenue through several key streams, primarily from the sale of medical supplies and pharmaceuticals to healthcare institutions. The company's revenue model is supported by a strong distribution network, which allows it to reach a wide array of clients in the healthcare sector. Additionally, Medipal Holdings benefits from partnerships with various manufacturers and suppliers, ensuring access to a broad portfolio of products. The company also engages in value-added services such as logistics and inventory management for its clients, further contributing to its earnings. By focusing on both product sales and service offerings, Medipal Holdings maintains a diversified revenue base that helps mitigate market risks.

Medipal Holdings Financial Statement Overview

Summary

Medipal Holdings demonstrates strong financial health with a consistent revenue and profit growth, a robust balance sheet with no debt, and historically effective cash flow management. Limitations in recent cash flow data slightly impact the overall financial assessment.

Income Statement

Medipal Holdings demonstrates strong profitability with a consistent gross profit margin around 6.8% and a net profit margin improving to 1.35% in TTM. Revenue growth is positive with a 7.24% increase from the previous annual report. The EBIT and EBITDA margins have shown resilience, indicating operational efficiency.

Balance Sheet

The company's balance sheet is robust with zero total debt, resulting in a debt-to-equity ratio of 0, which is favorable. The equity ratio stands at 32% in TTM, reflecting a solid equity base. The return on equity is strong at 7.9% in TTM, highlighting effective management of equity capital.

Cash Flow

While the operating cash flow is not available for TTM, the company had a substantial free cash flow in the previous period. Historically, operating cash flow to net income ratios have been healthy, but the absence of TTM data limits the assessment. Overall, cash flows have been managed effectively in prior periods.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.71T	3.67T	3.56T	3.36T	3.29T	3.21T
Gross Profit	254.44B	242.25B	246.66B	224.31B	217.44B	214.26B
EBITDA	90.71B	95.16B	92.73B	84.74B	71.64B	64.08B
Net Income	40.86B	40.28B	41.47B	38.81B	29.42B	23.93B
Balance Sheet
Total Assets	1.85T	1.82T	1.80T	1.70T	1.71T	1.68T
Cash, Cash Equivalents and Short-Term Investments	246.03B	261.41B	230.47B	195.03B	261.92B	241.52B
Total Debt	38.85B	4.17B	1.46B	7.38B	30.08B	30.58B
Total Liabilities	1.09T	1.07T	1.06T	1.02T	1.06T	1.04T
Stockholders Equity	616.58B	619.57B	600.35B	561.36B	530.30B	523.01B
Cash Flow
Free Cash Flow	0.00	51.70B	42.45B	2.64B	42.34B	18.78B
Operating Cash Flow	0.00	60.56B	61.84B	16.15B	61.22B	34.45B
Investing Cash Flow	0.00	-3.36B	-7.82B	-39.49B	-24.34B	-2.94B
Financing Cash Flow	0.00	-25.95B	-25.25B	-43.54B	-16.47B	-16.00B

Medipal Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2568.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7459, the sentiment is Negative. The current price of 2568 is above the 20-day moving average (MA) of 2541.83, below the 50-day MA of 2585.05, and above the 200-day MA of 2378.19, indicating a neutral trend. The MACD of -12.12 indicates Positive momentum. The RSI at 43.95 is Neutral, neither overbought nor oversold. The STOCH value of 15.32 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7459.

Medipal Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2784	―	$410.66B	14.27	5.93%	3.03%	4.35%	-5.14%
9987	―	$332.59B	13.30	8.26%	1.71%	0.65%	16.05%
7459	―	¥463.51B	12.78	6.81%	2.55%	3.51%	5.22%
3151	―	¥58.58B	9.01	―	4.66%	2.22%	21.19%
3349	―	¥593.42B	19.06	―	1.01%	3.73%	18.84%
8129	―	¥322.95B	14.62	―	1.72%	1.51%	3.14%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Medipal Holdings Corporate Events

Medipal Holdings Advances Treasury Stock Acquisition

Medipal Holdings Corporation announced the progress of its treasury stock acquisition, having purchased 400,000 shares for approximately JPY 1.07 billion between September 1 and September 30, 2025. This move is part of a larger plan resolved in May 2025 to acquire up to 4 million shares, aiming to strengthen shareholder value and optimize capital structure.

The most recent analyst rating on (JP:7459) stock is a Hold with a Yen2740.00 price target. To see the full list of analyst forecasts on Medipal Holdings stock, see the JP:7459 Stock Forecast page.

Medipal Holdings Advances Treasury Stock Acquisition Strategy

Medipal Holdings Corporation, a company listed on the Tokyo Stock Exchange, has been actively acquiring its own treasury stock as part of a strategic financial maneuver approved by its Board of Directors. Between August 1 and August 31, 2025, the company acquired 523,100 shares of common stock for approximately JPY 1.37 billion through market purchases. This acquisition is part of a larger plan to buy back up to 4 million shares by October 31, 2025, with a total budget of 8 billion yen. As of the end of August, Medipal has acquired 2,211,000 shares, amounting to over JPY 5.3 billion, indicating significant progress in its stock repurchase strategy.

The most recent analyst rating on (JP:7459) stock is a Hold with a Yen2740.00 price target. To see the full list of analyst forecasts on Medipal Holdings stock, see the JP:7459 Stock Forecast page.

Medipal Holdings Sees Q1 Sales Growth Amid Strategic Changes

Medipal Holdings reported a 3.9% increase in net sales to ¥945,159 million for the first quarter ending June 30, 2025, compared to the same period last year. Operating profit rose by 5.8%, and ordinary profit increased by 7.8%. Despite these gains, comprehensive income decreased by 35.1%. The company plans to maintain its dividend payments and has announced a share buyback for the fiscal year ending March 31, 2026. The removal of MVC CO., LTD. from the scope of consolidation was noted as it was absorbed by a wholly-owned subsidiary.

The most recent analyst rating on (JP:7459) stock is a Hold with a Yen2510.00 price target. To see the full list of analyst forecasts on Medipal Holdings stock, see the JP:7459 Stock Forecast page.